ROTHBLATT MARTINE A sold $5.0M of UTHR (indirect holdings)
ROTHBLATT MARTINE A (Chairperson & CEO) sold 9,500 indirectly-held shares of UNITED THERAPEUTICS Corp (UTHR) at an average of $528.58 ($522.87–$531.83, $5.02M total) across 10 trades on 2026-07-23 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest fact is the disclosed open-market sale amount ($5.02M) and the execution window (2026-07-23) under a 10b5-1 plan.
Market read
Traders may briefly reassess sentiment and positioning around UTHR due to CEO selling, but there is no new fundamental catalyst in the filing.
What to watch
Because the sale is indirect and under a pre-arranged plan, traders should avoid over-interpreting it as a change in outlook; watch for any concurrent operational news instead.
Background
The article is an SEC Form 4 insider transaction disclosure for United Therapeutics, reported by its Chairperson and CEO via an indirect holding.
Ticker impact
SEC Form 4 shows UTHR CEO sold $5.02M of shares on a 10b5-1 plan, with weighted-average prices $528.58 to $531.83.
Likely limited, short-lived sentiment impact; any move would be small versus broader fundamentals.
The filing is a primary-source Form 4 and the transaction size is notable, but it is explicitly under a pre-arranged 10b5-1 plan and provides no new company performance or guidance data.
Market effects
Minimal, as this is company-specific insider activity with no sector-wide regulatory or clinical signal.
None indicated.
None indicated.
Counterpoint
10b5-1 sales often reflect planned liquidity rather than bearish expectations, so the market may discount the signal quickly.
Key entities
- issuerUnited Therapeutics Corp
Subject of the Form 4 insider transaction disclosure.
- insiderROTHBLATT MARTINE A
Chairperson and CEO who reported the sale via indirect holdings.
